P1, N=282, Recruiting, Xencor, Inc. | N=212 --> 282

P1, N=22, Completed, Chugai Pharmaceutical | Active, not recruiting --> Completed | N=231 --> 22 | Trial completion date: Oct 2029 --> Jan 2026 | Trial primary completion date: Oct 2029 --> Jan 2026

ARC101 also demonstrated a favorable pharmacokinetic profile in cynomolgus monkeys, low immunostimulatory responses in ex vivo human donor assays, and robust biophysical properties compatible with standard antibody manufacturing. Collectively, these findings support the clinical advancement of ARC101 as a differentiated, CLDN6-specific bispecific immunotherapy with exceptional tumor selectivity and optimized T cell activity for the treatment of solid tumors.

And the 11.1 MBq [¹⁷⁷Lu]Lu-DOTA- IMAB027 group significantly inhibited tumor growth, prolonged survival, and showed lower toxicity than non-radioactive drug treatment groups. ⁸⁹Zr/¹⁷⁷Lu-labeled IMAB027 holding promise as a potentially viable therapeutic approach for clinical management of gynecological cancers.

P1, N=70, Not yet recruiting, Xencor Inc.

Post-carboplatin analysis revealed increased CLDN6 expression, EMT-related gene changes, and enhanced T-cell infiltration, which were associated with the synergistic effect of SAIL66. Our study provides insights into the biology and plasticity of CLDN6-positive cells in EOC heterogeneity and highlights the clinical significance of CLDN6-targeting therapies for ovarian cancer treatment.

P1/2, N=73, Terminated, BioNTech SE | Active, not recruiting --> Terminated; Sponsor decision

P1, N=80, Recruiting, Context Therapeutics Inc. | Trial primary completion date: Jul 2027 --> Apr 2027

P1, N=231, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting

P1, N=212, Recruiting, Xencor, Inc. | Completed --> Recruiting | N=60 --> 212 | Trial completion date: May 2025 --> Dec 2028 | Trial primary completion date: May 2025 --> Dec 2027

P1, N=60, Completed, Xencor, Inc. | Recruiting --> Completed | N=212 --> 60 | Trial completion date: Dec 2028 --> May 2025 | Trial primary completion date: Dec 2027 --> May 2025

P1/2, N=73, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting | N=330 --> 73 | Trial completion date: Apr 2026 --> Dec 2025